SCHEDULE: Vanguard Discloses 5.57% Stake in Coeptis Therapeutics

Vanguard Capital Management has reported beneficial ownership of 5.57% of Coeptis Therapeutics Holdings Inc. common stock as of March 31, 2026.

Summary

• Vanguard Capital Management, along with its affiliates, now beneficially owns 346,975 shares of Coeptis Therapeutics Holdings Inc. common stock.
• This holding represents 5.57% of the total class of securities.
• The filing indicates Vanguard has sole dispositive power over these shares.
• Vanguard Capital Management is classified as an investment adviser and an investment company.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of influencing control of the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it indicates significant institutional interest from a major player, but it is a passive disclosure and not an active investment recommendation or strategic partnership.

Positives

• Vanguard's significant stake suggests confidence in Coeptis Therapeutics' long-term prospects, potentially attracting further institutional investment.
• The filing confirms Vanguard's role as a substantial shareholder, which can lend stability and credibility to the company.

Negatives

• The filing does not contain any negative financial results or operational challenges for Coeptis Therapeutics.

Risks

• The primary risk for Coeptis Therapeutics is the potential for Vanguard to divest its stake, which could negatively impact share price.
• As an investment adviser, Vanguard's investment decisions are subject to market conditions and fund performance, which could lead to changes in holdings.

Future Outlook

The filing does not contain forward-looking statements or guidance from Coeptis Therapeutics. Vanguard's future actions regarding its stake are not specified.

Management Comments

• "In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by Vanguard Capital Management LLC and the following affiliates of Vanguard Capital Management LLC or business divisions of such affiliates: Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC and Vanguard Investments Australia Ltd."
• "This Schedule 13G includes securities held by Vanguard funds, or sleeves thereof, over which Vanguard Capital Management LLC exercises dispositive power, in addition to securities held by clients over which the affiliates or business divisions of such affiliates indicated above exercise dispositive and/or voting power."
• "This Schedule 13G does not include securities, if any, beneficially owned by other subsidiaries or affiliates of Vanguard Capital Management LLC, or business divisions of such subsidiaries, whose ownership of securities is disaggregated from that of the reporting business unit in accordance with such release."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that a significant stake by a large institutional investor like Vanguard in a biotechnology or therapeutics company like Coeptis Therapeutics often signals a belief in the company's pipeline or market potential, though it is a passive filing and does not represent an endorsement of management strategy.

Comparison to Industry Standards

• Vanguard's acquisition of a 5.57% stake is a notable threshold for institutional ownership in a company of Coeptis Therapeutics' size, indicating a substantial investment.
• Many publicly traded biotechnology companies aim to attract institutional investors with holdings in the 5-10% range to enhance credibility and liquidity.

Stakeholder Impact

• Shareholders: The increased institutional ownership may lead to greater market liquidity and potentially a more stable share price, but also introduces the risk of large sell-offs by Vanguard.
• Creditors: Increased institutional interest can be seen as a positive signal for the company's financial stability.
• Management: The filing is a passive disclosure and does not directly impact management's operational responsibilities, but it signifies external validation of the company's existence and potential.

Next Steps

• Vanguard will continue to monitor Coeptis Therapeutics' performance and strategic developments.
• Coeptis Therapeutics will continue its operations and strategic initiatives, subject to market conditions and regulatory approvals.

Key Dates

Recommendation

This filing is a passive disclosure of beneficial ownership by a large institutional investor. While Vanguard's stake suggests some level of confidence, it does not provide new operational or financial information about Coeptis Therapeutics itself. Therefore, a 'hold' recommendation is appropriate, advising investors to maintain their current positions while awaiting further company-specific news or performance updates.

Keywords

Coeptis Therapeutics, Vanguard Capital Management, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Investment Adviser